Developing a treatment to stop the COVID-19 Delta variant - a University of Utah study with Johns Hopkins University has a goal to do just that.
The trial’s intended to stop covid-related hospitalizations and to keep the virus from spreading.
Recent statewide data shows the Delta variant makes up for 80 percent of all new infections we’re seeing in Utah.
Medical leaders across the state expect those numbers to continue rising.
The trial in question involves a potential variant antibody treatment.
Officials are currently two-thirds of the way through the trials with everything expected to wrap up in August.
Since the study is volunteer-based, they need people who’ve tested positive for COVID-19 to join within five days of the initial diagnosis.
Johns Hopkins Infectious Disease Doctor David Sullivan explained how the study works.
He shared that it's a randomized control trial and participants have a 50 percent chance of getting antibodies and a 50 percent chance of getting a control.
“You're participating and fighting covid. We do pay you to participate, those details you can find out from your local Utah team,” shared Dr. Sullivan.
He said so far Salt Lake’s been a great location for this trial.
It’s one of 12 active sites conducting the study now.
If you’re interested in joining, visit the study's website to find out if you’re eligible.